Collectively, these findings indicate the value of exploring the potential of Piezo2 as a biomarker for IBS, providing a potential therapeutic target for the treatment of visceral pain and abnormal GI motility. This evidence concerns the gene PIEZO2 and irritable bowel syndrome.